This is not the most recent version of the article. View current version (10 MAR 2015)

Intervention Review

You have free access to this content

Hormone therapy for preventing cardiovascular disease in post-menopausal women

  1. Caroline Main1,*,
  2. Beatrice Knight2,
  3. Tiffany Moxham3,
  4. Rafael Gabriel Sanchez4,
  5. Luis Maria Sanchez Gomez5,
  6. Marta Roqué i Figuls6,
  7. Xavier Bonfill Cosp7

Editorial Group: Cochrane Heart Group

Published Online: 30 APR 2013

Assessed as up-to-date: 20 APR 2010

DOI: 10.1002/14651858.CD002229.pub3


How to Cite

Main C, Knight B, Moxham T, Gabriel Sanchez R, Sanchez Gomez LM, Roqué i Figuls M, Bonfill Cosp X. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD002229. DOI: 10.1002/14651858.CD002229.pub3.

Author Information

  1. 1

    Peninsula College of Medicine and Dentistry, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  2. 2

    University of Exeter Medical School, NIHR Exeter Clinical Research Facilt, Exeter, UK

  3. 3

    Florida Atlantic University, Wimberly Library, Boca Raton, Florida, USA

  4. 4

    Hospital Universitario de la Paz, Universidad Autónoma de Madrid, Instituto de Investigacion IdiPAZ, Red Espanola de Investigacion Cardiovascular RD/12/0042/0008, Madrid, Spain

  5. 5

    Instituto de Salud Carlos III, Agencia de Evaluacion Tecnologias Sanitarias, Madrid, Spain

  6. 6

    CIBER Epidemiología y Salud Pública (CIBERESP), Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Catalunya, Spain

  7. 7

    CIBER Epidemiología y Salud Pública (CIBERESP), Spain - Universitat Autònoma de Barcelona, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Catalonia, Spain

*Caroline Main, Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, Noy Scott House, Barrack Road, Exeter, EX2 5DW, UK. carriemain24@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (10 MAR 2015)

[Figure 1]
Figure 1. Figure 1: Process of study selection for the review
[Figure 2]
Figure 2. Figure 2: Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Figure 3: Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Funnel plot of comparison: HT versus placebo in primary and secondary prevention, outcome: 5.1 Death (all causes).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 1 Death (all causes).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 2 Death (CV causes).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 3 Non-fatal MI.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 4 Stroke.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 5 Angina.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 6 Venous thromboembolism.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 7 Pulmonary embolism.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Estrogen vs placebo in primary prevention, Outcome 8 Angioplasty.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 1 Death (all causes).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 2 Death (CV causes).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 3 Non-fatal MI.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 4 Stroke.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 5 Angina.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 6 Venous thromboembolism.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 7 Pulmonary embolism.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 8 Death (all causes): time on treatment.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 9 Stroke: time on treatment.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 10 Venous thromboembolism: time on treatment.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Combination HT vs placebo in primary prevention, Outcome 11 Non-fatal MI: time on treatment.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 1 Death (all causes).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 2 Death (CV causes).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 3 Non-fatal MI.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 4 Stroke.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 5 Angina.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 6 Venous thromboembolism.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 7 Pulmonary embolism.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Estrogen vs placebo in secondary prevention, Outcome 8 Angioplasty.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 1 Death (all causes).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 2 Death (CV causes).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 3 Non-fatal MI.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 4 Stroke.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 5 Angina.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 6 Venous thromboembolism.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 7 Pulmonary embolism.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 8 Coronary artery by-pass surgery.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 9 Angioplasty.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 10 Death (CV causes): time on treatment.
[Analysis 4.11]
Analysis 4.11. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 11 Non-fatal MI: time on treatment.
[Analysis 4.12]
Analysis 4.12. Comparison 4 Combination HT vs placebo in secondary prevention, Outcome 12 Venous thromboembolism: time on treatment.
[Analysis 5.1]
Analysis 5.1. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 1 Death (all causes).
[Analysis 5.2]
Analysis 5.2. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 2 Death (CV causes).
[Analysis 5.3]
Analysis 5.3. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 3 Non-fatal MI.
[Analysis 5.4]
Analysis 5.4. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 4 Stroke.
[Analysis 5.5]
Analysis 5.5. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 5 Angina.
[Analysis 5.6]
Analysis 5.6. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 6 Venous thromboembolism.
[Analysis 5.7]
Analysis 5.7. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 7 Pulmonary embolism.
[Analysis 5.8]
Analysis 5.8. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 8 Coronary artery by-pass surgery.
[Analysis 5.9]
Analysis 5.9. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 9 Angioplasty.
[Analysis 5.10]
Analysis 5.10. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 10 Death (all causes): time on treatment.
[Analysis 5.11]
Analysis 5.11. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 11 Death (CV causes): time on treatment.
[Analysis 5.12]
Analysis 5.12. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 12 Non-fatal MI: time on treatment.
[Analysis 5.13]
Analysis 5.13. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 13 Stroke: time on treatment.
[Analysis 5.14]
Analysis 5.14. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 14 Angina: time on treatment.
[Analysis 5.15]
Analysis 5.15. Comparison 5 HT vs placebo in primary and secondary prevention, Outcome 15 Venous thromboembolism: time on treatment.